Compare Paychex, Inc. (PAYX) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Paychex, Inc. vs Zimmer Biomet Holdings Inc — how do they compare? Paychex, Inc. trades at $104.21 (market cap $37.19B), while Zimmer Biomet Holdings Inc trades at $89.37 (market cap $16.95B). The key difference: Paychex, Inc. is far larger — about 2.2× Zimmer Biomet Holdings Inc's market cap, and Paychex, Inc. pays the higher dividend (4.56%). Which is the better fit depends on your goals — on Pluang, investors hold Paychex, Inc. for 56 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| PAYX | ZBH | |
|---|---|---|
Market Cap | $37.19B | $16.95B |
Volume | 3,344,316 | 2,505,240 |
Sector | Industrials | Health |
52-Week High | $128.59 | $103.98 |
52-Week Low | $85.57 | $79.58 |
Typical Hold Time | 56 Days | 89 Days |
Enterprise Value | $40.87B | $24.02B |
Dividend Yield | 4.56% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Paychex (PAYX) trades at $104.62, up 3.02% today, with a mixed technical outlook showing bullish overall signals but bearish moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.34 beating the $1.32 estimate, and maintains robust profitability with a 27.35% net income margin. Recent news highlights a 14% stock decline despite earnings strength, raising questions about dividend sustainability amid investor focus on cash flow.
The outlook is cautiously optimistic, with a consensus price target of $111 suggesting modest upside. Key opportunities include steady revenue growth and high margins, but risks involve labor market sensitivity and elevated valuation multiples. The stock's recent volatility reflects divergent analyst views, with 67.74% holding a neutral rating.
Zimmer Biomet (ZBH) trades at $88.70, up 0.24% on the day, with a bearish technical outlook but strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.07 exceeding expectations. Revenue growth remains steady, reaching $8.23B in 2025, while profitability metrics like a 69.87% gross margin and 9.48% net margin reflect operational efficiency. Recent corporate news includes a $0.24 quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The investment outlook is mixed, with analyst consensus leaning hold (52.38%) but a price target of $103.11 suggesting 16% upside. Key opportunities include sustained earnings beats and strategic initiatives, while risks involve rising debt levels, competitive pressures, and technical bearish signals. The stock's current valuation at a P/E of 21.57 appears reasonable relative to growth prospects, but investors should weigh fundamental strength against near-term technical weakness and macroeconomic headwinds in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
